Clinical Trial Detail

NCT ID NCT01945775
Title A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors BioMarin Pharmaceutical
Indications

breast carcinoma

Therapies

Gemcitabine

Capecitabine

Vinorelbine

Talazoparib

Eribulin

Age Groups: adult

Additional content available in CKB BOOST